Dying Together: How Group Psilocybin Therapy Turns Solitary Death Anxiety into Shared Meaning

The Loneliest Room in Medicine

Facing a terminal diagnosis is, clinically speaking, a solitary event. The scan results are delivered to one patient. The prognosis is discussed in a private room. Even the landmark psilocybin trials that reshaped palliative psychiatry over the past decade — Roland Griffiths’ and Matthew Johnson’s work at Johns Hopkins, Robin Carhart-Harris’s neuroimaging studies at Imperial College — have largely followed a one-therapist, one-patient model. It works. Single high-dose psilocybin sessions paired with individual psychotherapy have repeatedly produced rapid, durable reductions in death anxiety and depression among cancer patients. But that model has a structural problem: it’s expensive, therapist-intensive, and nearly impossible to scale to the number of people who are, right now, dying with unresolved existential distress.

A new study published in Frontiers in Public Health by Vivian Tsang, Pamela Kryskow, Colleen Watler, Pierre Allard, and Shannon Dames asks a deceptively simple question: what if the dying didn’t have to do this alone? What if the container for a psilocybin experience wasn’t a single therapist’s office, but a community that had already practiced being vulnerable together before the medicine ever entered the room?

The Model: Sangha Meets Clinical Protocol

The research team, working across the University of Oxford, University of British Columbia, and Vancouver Island University, built and tested a hybrid group therapy structure specifically for patients with terminal diagnoses. Over one year — November 2021 to November 2022 — they ran four sequential cohorts totaling 25 participants, delivering 31 individual psilocybin-assisted therapy (PaT) sessions in a “communities of practice” (CoP) framework.

The structure matters as much as the medicine. Each cohort met once weekly for six to eight sessions — some before the psilocybin dosing (preparation) and some after (integration) — conducted virtually as a group. Only the actual dosing session happened in person, one-on-one with clinical support. Everything else — the relationship-building, the psychoeducation, the emotional processing, the grief work — happened collectively, on video calls, among people who were all facing the same unbearable fact: their time was limited.

This is a critical design choice. In most individual PaT protocols, the therapeutic alliance is built with a single clinician in a handful of preparatory sessions. Here, the group itself becomes a second layer of relational scaffolding, one that persists independent of any single therapist’s availability. Patients weren’t just being prepared for a psychedelic experience — they were being folded into a community of people who understood, without needing it explained, what it means to metabolize mortality in real time.

What the Data Show

The numbers are notable for a population this fragile. Completion rates reached 84% — remarkably high given that participants were, by definition, managing advancing terminal illness, which brings unpredictable hospitalizations, fatigue, and clinical setbacks that typically erode adherence to any structured program. Using semi-structured interviews analyzed through iterative thematic coding, the research team identified three consistent outcome domains: enhanced trust in self, an improved outlook on life, and a strengthened sense of connection to community.

What’s striking is how participants described arriving at those outcomes. It wasn’t primarily attributed to the pharmacology of psilocybin acting alone on the brain’s 5-HT2A receptors, triggering the acute neuroplasticity and default mode network disintegration that researchers like Carhart-Harris have mapped so precisely. Participants pointed to something relational: peer support, felt safety within the group, and shared regulation practices as the mechanisms that made the medicine session itself feel survivable and meaningful. The psilocybin appears to have been the catalyst, but the community was described as the container that made the catalytic moment integrate into lasting change rather than dissipate as a peak experience with no home to return to.

This aligns closely with what Stephen Porges’ polyvagal theory would predict. A nervous system approaching an altered state of consciousness — let alone one already burdened by the chronic HPA axis activation of terminal illness — needs cues of safety to shift out of sympathetic or dorsal vagal shutdown states and into the ventral vagal, socially engaged state where deep processing becomes possible. A room full of strangers meeting for the first time on the day of dosing cannot offer that kind of physiological safety as reliably as a group that has spent six to eight weeks building trust together. The CoP structure, in effect, pre-loads the nervous system regulation that individual protocols must attempt to build from scratch in a compressed timeframe.

Echoes of Grof, and the Return of Communal Witnessing

There’s a lineage worth naming here. Stanislav Grof and Christina Grof’s Holotropic Breathwork was, from its inception, a group modality — built on the premise that non-ordinary states of consciousness are processed more completely when witnessed by a community rather than confined to a private therapeutic dyad. Grof observed decades ago that group settings allow participants to see their own psychological material reflected in others, normalizing the terror, grief, and awe that arise when confronting death, birth, and the boundaries of ego.

This study is, in a sense, a controlled clinical descendant of that insight — applied specifically to the population for whom mortality isn’t a metaphor but a medical timeline. What Grof called the “collective unconscious” surfacing in group work, the modern language of trauma-informed care would call co-regulation, and what contemplative traditions have called sangha for millennia — the study’s participants seem to have experienced all three simultaneously.

The mystical experiences and ego dissolution documented in individual psilocybin trials for death anxiety are typically framed as intrapsychic events: an individual confronting their own dissolution and finding, on the other side, a felt sense of continuity or interconnectedness. What this study suggests is that when that dissolution happens inside a community that has already rehearsed vulnerability together, the resulting meaning doesn’t stay locked inside one person’s changed relationship to their own mortality — it becomes a shared narrative, witnessed and reinforced by others who will, in some cases, die within months of the same cohort.

Honest Limits

The authors are careful to flag that feedback was mixed. Not every participant thrived in a group format; some likely needed more individualized attention than a shared virtual structure could provide, and the qualitative design — while appropriate for a first feasibility study — cannot isolate which specific ingredient (the psilocybin, the group, the regulation curriculum, or their interaction) drove which outcome. With 25 participants and no control arm, this is a proof-of-concept, not a definitive trial. But feasibility and safety, in a population this vulnerable, are not small findings — they’re the necessary first rung before any scaled implementation.

Why This Matters Beyond the Clinic

Psilocybin-assisted therapy’s greatest barrier to reaching the people who need it isn’t regulatory approval alone — it’s cost and clinician bandwidth. A model requiring one highly trained therapist per patient for dozens of contact hours cannot serve palliative care populations at any meaningful scale. This study offers a genuinely novel answer: distribute the relational labor across a community, reserve the intensive one-on-one support for the dosing session itself, and let peer witnessing do work that would otherwise require additional clinical hours.

For practitioners, this reframes psychedelic-assisted therapy for the dying not as a private confrontation with the void, but as a communal rite of passage — one where the group’s presence becomes part of the medicine. For researchers, it opens a testable hypothesis: that relational safety and co-regulation, not just receptor pharmacology, are quantifiable active ingredients in psychedelic outcomes, and that group formats may not be a compromise on efficacy but a distinct therapeutic mechanism in their own right.

And for anyone facing the end of their own life, it offers something quietly radical: you don’t have to do this part alone.